Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: J Geriatr Oncol. 2016 Feb 23;7(3):176–186. doi: 10.1016/j.jgo.2016.01.011

Figure 2. Figure 2a-f. Propensity score-weighted cumulative all-cause and cancer-specific mortality among patients with non-metastatic rectal cancer who received postoperative 5-FU or capecitabine alone vs. no postoperative chemotherapy by age group (panels a-d) and postoperative oxaliplatin vs. postoperative 5-FU/capecitabine alone among patients age 66-74 years (panels e-f).

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

In panels a-d, the blue (solid) line represents the cumulative incidence of the specific outcome (i.e., all-cause or cancer specific mortality) for individuals who received postoperative 5-FU/capecitabine alone while the red (dashed) line represents the cumulative incidence of the outcome for individuals who did not receive postoperative chemotherapy. In panels e-f, the blue (solid) line represents the cumulative incidence of the outcome for individuals who received postoperative oxaliplatin and the red (dashed) line represents the cumulative incidence of the outcome for individuals who received postoperative 5-FU/capecitabine alone.